# Firibastat in Treatment-resistant Hypertension

> **NCT04277884** · PHASE3 · COMPLETED · sponsor: **Quantum Genomics SA** · enrollment: 515 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Firibastat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04277884
- **Lead sponsor:** Quantum Genomics SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-25
- **Primary completion:** 2022-08-30
- **Final completion:** 2022-09-20
- **Target enrollment:** 515 (ACTUAL)
- **Last updated:** 2022-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04277884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04277884, "Firibastat in Treatment-resistant Hypertension". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04277884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*